Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

AstraZeneca abandons plans to launch Vaxzevria COVID-19 vaccine in U.S. 

By Brian Buntz | November 10, 2022

AstraZenecaAstraZeneca (LON:AZN) was among the first companies to develop a COVID-19 vaccine, but the firm has given up on marketing its Vaxzevria vaccine in the U.S. The company’s CEO, Pascal Soriot, announced that it had asked the FDA to withdraw its regulatory paperwork for Vaxzevria.

The vaccine developed jointly with Oxford University saw considerable success in Europe and elsewhere. But the replication-deficient chimpanzee adenovirus ChAdOx1/AZD1222 has seen waning use as mRNA-based vaccines have come to dominate the market.

In the third quarter of 2022, sales of the vaccine dropped 83% to $173 million. Earlier this year, developing countries refused tens of millions of vaccine doses.

After giving up on plans to market its COVID-19 vaccine in the U.S., AstraZeneca will focus on the monoclonal antibody cocktail Evusheld (tixagevimab/cilgavimab).

AstraZeneca developed Evusheld in collaboration with researchers at Vanderbilt University. Dr. James E. Crowe Jr., Robert Carnahan and other Vanderbilt researchers first identified the two antibodies and licensed them to AstraZeneca in June 2020.

To date, Evusheld is the only pre-exposure prophylaxis (PrEP) of COVID-19 to receive emergency use authorization (EUA). Specifically, the EUA covers its use in immunocompromised individuals unlikely to respond strongly to COVID-19 vaccination.

In October, AstraZeneca announced that Evusheld reduced the likelihood of hospitalization and death in the Phase 3 TACKLE study, which focused on adults with mild-to-moderate COVID-19.

The antibody cocktail has a durable effect. According to data from the Phase 3 PROVENT study, Evusheld offers protection against COVID-19 for at least six months.

The antibody cocktail, however, may not hold up to some variants, according to the FDA. In addition, the agency warned in October that various omicron subvariants had reduced susceptibility to Evusheld.

AstraZeneca plans to launch a rebooted version of Evusheld by the second half of 2023.

AZN shares were up 6.62% to $65.09. The company’s stock is up 11.63% thus far this year.

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

institut pasteur dakar IPD African Union vaccine investment
African Union vaccine initiative receives $45M
Sen-Jam Pharma, KVK-Tech partnering for manufacturing and formulation for anti-inflammatory injectables
This image shows the Moderna logo.
Moderna resizes its manufacturing footprint for a post-pandemic era
This is the logo of Pfizer.
Pfizer to close Durham and Morrisville, North Carolina facilities amid major restructuring effort
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE